Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6249

Provisional Schedule

Committee meeting: 1 03 December 2025
Expected publication 04 March 2026

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Janssen-Cilag (daratumumab, bortezomib)
Others Department of Health and Social Care
  Heath Technology Wales
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer52
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kevin Karawa Leukaemia Trust
  Leukaemia Cancer Society
  Leukaemia Care
  Leukaemia UK
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society of Interventional Radiology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Myeloma Society
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Advanz Pharma (lenalidomide)
  Amarox (lenalidomide)
  Aspire (bortezomib)
  Aurobindo Pharma (bortezomib)
  Biocon Pharma (lenalidomide)
  Biotech Pharma (bortezomib)
  Bristol Myers Squibb (lenalidomide, thalidomide)
  Dr Reddy’s Laboratories (bortezomib)
  Grindeks Kalceks UK (lenalidomide)
  MSN laboratories Europe (bortezomib)
  Mylan (lenalidomide)
  Pfizer (bortezomib)
  Piramal Critical Care (lenalidomide)
  Ranbaxy UK (bortezomib, lenalidomide)
  Sandoz (bortezomib, lenalidomide)
  Teva UK (lenalidomide)
  Thornton & Ross (bortezomib, lenalidomide)
  Tillomed Laboratories (bortezomib)
  Zentiva (thalidomide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
13 May 2025 Invitation to participate
17 March 2025 - 14 April 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6249
17 March 2025 In progress. Scoping commencing
19 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual